论文部分内容阅读
目的:对风湿性心脏病左房室瓣狭窄伴心房纤颤患者行药学服务,观察临床路径干预效果。方法:择取本院收治的风湿性心脏病左房室瓣狭窄伴心房纤颤患者198例随机分为参照组与实验组,每组各99例。对参照组患者行常规临床路径管理;实验组患者在此基础上接受药学监护。对比两组患者的抗凝治疗达标率、不良事件发生率、住院费用、住院时间以及药占比。结果:两组患者在不良事件发生率、住院费用、住院时间以及药占比方面的数据均不存在明显差异,P>0.05,而实验组患者的抗凝治疗达标率与参照组患者对比,统计学意义显著(P<0.05)。结论:对风湿性心脏病左房室瓣狭窄伴心房纤颤患者行药学服务,有利于提高患者的抗凝治疗效果,安全性能显著,值得应用及推广。
OBJECTIVE: To perform pharmacological services on patients with left atrioventricular valve stenosis and atrial fibrillation in rheumatic heart disease and to observe the effect of clinical pathway intervention. Methods: A total of 198 patients with left atrioventricular valve stenosis and atrial fibrillation in our hospital were randomly divided into control group and experimental group, with 99 cases in each group. Patients in the reference group underwent routine clinical path management; patients in the experimental group received medical supervision on this basis. Comparing the two groups of patients anticoagulant rate of compliance, the incidence of adverse events, hospitalization costs, length of stay and medicine accounted for. Results: There was no significant difference between the two groups in the incidence of adverse events, hospitalization costs, length of hospital stay and the proportion of drugs, P> 0.05, while the experimental group patients anticoagulant treatment compliance rate compared with the reference group of patients, statistics Significant significance (P <0.05). Conclusion: Pharmacological services for patients with left atrioventricular valve stenosis and atrial fibrillation in patients with rheumatic heart disease are helpful to improve the anticoagulant effect of patients and have significant safety performance. They are worthy of application and promotion.